ArticleScientific reports2026
Phytochemical profile and chemosensitizing anticancer activity of Mitragyna speciosa and mitragynine.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study examined the phytochemical composition, antioxidant efficacy, and cytotoxic properties of Mitragyna speciosa (kratom) extracts and its principal alkaloid, mitragynine. The extracts exhibited significant antioxidant properties, and chemical analysis verified mitragynine as the principal alkaloid, aligning with the distinctive phytochemical profile of M. speciosa. In vitro cytotoxicity studies demonstrated that both kratom extract and mitragynine suppressed cancer cell proliferation (A549, KKU213C, and HeLa cancer cell lines) in a concentration- and time-dependent manner, with mitragynine displaying greater potency compared to the crude extract, especially against cholangiocarcinoma cells. Importantly, synergistic cytotoxic effects were noted when kratom extract or mitragynine was combined with standard chemotherapeutic agents across various cancer cell lines, especially HeLa cervical cancer. These effects correlated with diminished expression of the anti-apoptotic protein BCL-2. In general, the results show that M. speciosa extract and mitragynine are chemosensitizers that could make standard chemotherapy work better. Additional research is necessary to clarify the molecular mechanisms involved and to confirm these effects in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.